News - first half of 2019

2019, July the 1st

Creation of the new VirPath spin-off VAXXEL

VirParth announces the creation of VAXXEL with the support of the UCBL subsidiaries Lyon Ingenierie Projets and EZUS, the SATT Pulsalys, the Technology Research Platform VirNext and TRANSGENE. Based on our patented polyvalent viral vaccine platform METAVAC® and a pilot process of production using the proprietary DuckCelt®-T17 cell line, VAXXEL is developing an innovative live attenuated vaccine candidate to fight pneumoviruses. 

2019, June the 19th

Reviving old drugs to fight viral infections.

VirPath is highlighted in the two months science magazine of INSERM (From science to health, magazine number #43 of June 2019) for its drugs repurposing strategy.

SS43_WEB%281%29 12.pdf
Document Adobe Acrobat 251.0 KB
SS43_WEB%281%29 13.pdf
Document Adobe Acrobat 198.1 KB

2019, June the 17th

VirPath and Calixar patent granted in the United States on an innovative splitting method for preparing vaccine viral antigens US 10144917. 

VirPath announces the grant of its patent for the preparation of influenza antigens using an innovative splitting approach for the formulation of novel vaccines by the United States Patent and Trademark Office, notably with regard to the foreseen impact of the current REACH Regulation 1907/2006/EC on the putative prohibition of endocrine disruptors such as Triton X-100. 


This patent is issued from a fruitful collaboration with the company CALIXAR that took the operating license, and the Technology Research Platform VirNext.

2019, May the 9th

Results from our collaboration with the Center for Infection and Immunity of Lille (CIIL, U1019-UMR8204) on TLR-5 agonist flagellin and Influenza A Virus.

This study highlights the therapeutic potential of the flagellin to control the replication of the influenza virus.

2019, March the 27th

Results from our collaboration with the Infectious Disease Research Centre (Pr. Guy BOIVIN, Laval University, Quebec) on hMPV infection and NLRP3 inflamasome have been published in Plos Pathogen.

We hereby suggest that the blockade of IL-1β production, by using NLRP3 inflammasome inhibitors, might be a novel potential strategy for the therapy and prevention of hMPV infection.

2019, March the 27th

METAVAC - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.

We are proud to announce that the Technology Transfer Accelerator Office PULSALYS will fund our METAVAC R&D program. Based on patented technologies, this program aims to development a new live attenuated viral vaccine and an up scalable avian cell line-based process of production. 

2019, March the 27th

The first scientific day of the french influenza research network, ResaFLU, was organized by VirPath. 

2019, March the 13th

Fonds French Tech Seed : le consortium Pouss@LYS labellise 6 startups DeepTech dont 4 projets de PULSALYS
Poussatlys press release.pdf
Document Adobe Acrobat 251.6 KB

2019, February the 27th

Our last review on drug repurposing approaches for the treatment of influenza viral infection has been accepted in Frontiers in Immunology.

2019, February the 15th

Results from our collaboration with ICBMS/GEMBAS on SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring have been published in Vaccine.

We hereby report an imaging surface plasmon resonance (SPRi) assay for the quantification of both inactivated vaccine influenza antigens and viral particles derived from egg- and cell-based production samples, respectively.

2019, February the 6th

REPURPOSING - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.

We are proud to announce that The Technology Transfer Accelerator Office PULSALYS will fund our R&D program on drug repurposing and pre-clinical evaluation of drugs for new antimicrobial indication. These technologies were patented in 2018.

2019, February the 4th

Our publication on the repurposing of Diltiazem as an innovative host targeted influenza inhibitor has been published in Frontiers in Immunology.

Licensed to Signia Therapeutics, Diltiazem is currently evaluated in a phase II clinical trial for the treatment of patients with severe influenza infections in intensive care units (FLUNEXT TRIAL PHRC identifier NCT03212716).

2019, January the 23th

Our publication in Journal of Virolgy concerning the functional interactions of cellular p53 and CPSF4 factors with NS1 and their impact on Influenza A virus replication.

2019, January the 23th

Results from our collaborative ANR project OPTIVAC have been published in NPJ Vaccines.

2019, January the 23th

Signia Therapeutics is highlighted in the innovation newsletter of the Centre National de Recherche Scientifique (CNRS), as an innovative start-up working on drug repurposing to counteract respiratory infections.

2019, January the 18th

Andrés Pizzorno' article "Fighting the damocles sword of infectious diseases through drug repurposing" was published in European Biopharmaceutical Review (EBR).

Fighting the damocles sword of infectious diseases through drug repurposing.
This article is taken from European Biopharmaceutical Review January 2019, pages 82-85. © Samedan Ltd
EBR article.pdf
Document Adobe Acrobat 161.1 KB